A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 173 (planned)
- Started
- Nov 2026
- Main results expected
- Oct 2029
- Fully finished
- Apr 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A only: Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period
Measured over: Up to 21 days from the initiation of first dose of study treatment
Occurrence of treatment emergent adverse events (TEAEs) by grade, seriousness, and relatedness
Measured over: Up to approximately 3 years from first dose of study treatment
Occurrence of dose interruptions, reductions, and discontinuation of BNT3210 due to TEAEs
Measured over: Up to approximately 3 years from first dose of study treatment
Part B only: Objective response rate (ORR)
Measured over: Up to approximately 3 years from first dose of study treatment
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07886684 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC